We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NOXOF market cap is 13.15M. The company's latest EPS is AUD -0.0515 and P/E is -1.36.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 3.75M | 8.33M | 5.66M | 5.43M | 6.01M |
| Operating Income | -12.11M | -9.13M | -15.59M | -9.78M | -10.65M |
| Net Income | -11.22M | -272k | -9.35M | -18.67M | -15.06M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 4.3M | 20.07M | 47.85M | 26.59M | 10.13M |
| Total Liabilities | 5.75M | 7.19M | 7.08M | 2.48M | 1.06M |
| Total Equity | -1.45M | 12.87M | 40.78M | 24.12M | 9.07M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -9.78M | -11.14M | -8.85M | -13.73M | -10.95M |
| Investing | -3k | 338k | 225k | N/A | 124k |
| Financing | 75k | 14.99M | 28.33M | 976k | -178k |
| Market Cap | 13.15M |
| Price to Earnings Ratio | -1.36 |
| Price to Sales Ratio | 3.4 |
| Price to Cash Ratio | 6.8 |
| Price to Book Ratio | 2.25 |
| Dividend Yield | - |
| Shares Outstanding | 292.24M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 2.3k |
| 52 Week Change | 50.00% |
| 52 Week High | 0.045 |
| 52 Week Low | 0.03 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Noxopharm Ltd (PK) |
| Address |
level 20 sydney, new south wales 2067 |
| Website | https://www.noxopharm.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
